Telitacicept for children with IgA vasculitis kidney disease
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a targeted medication called Telitacicept for children and teens with kidney inflammation caused by IgA vasculitis. It aims to reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 3 to 17 years old
- Diagnosed with IgA vasculitis that has spread to the kidneys
- High protein in the urine (protein/creatinine ratio of 1 mg/mg or more)
- Good kidney function (eGFR 60 mL/min or higher)
- No serious infections or immune system problems
- No prior B-cell treatments or certain transplant history
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if telitacicept can safely help children aged 5–18 with IgA nephropathy or IgA vasculitis nephritis. It aims to reduce protein in the urine and protect kidney function.
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
This trial tests telitacicept in people with IgA nephropathy that has not responded well to standard care. It aims to reduce harmful kidney inflammation and protein leakage in the urine.
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
Hear when a new IgAVN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.